leisure time -WSS

leisure time

author：hotspot 2025-10-01 15:00:09 - browse：8

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Wayne Brady comes out as pansexual: 'Free to love whomever I want'

focus

WSS

Even great ERs can’t make up for American health disparities

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Do digital therapeutics have a future in medicine?

South Korea throws huge K

Juul spent big to court Black leaders to promote its e

Quicker fix for pulse oximeters urged during FDA public meeting

focus

leisure time

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

explore

23andMe had bad news about my health. I wish a person had delivered it

How to use technology to prevent future drug shortages

How to save PrEP access — and even expand it

Friends ask where James Watson's attitudes about race came from

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

General Catalyst, Summa Health deal will turn on physician buy

Moonlake's readout produced a cash windfall. Risks remain

Wegovy’s successful heart trial raises vital question about weight loss

Trump demands the U.S. pay no more for drugs than other countries … again

Anavex keeps shifting the goalposts in its clinical trials

knowledge

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Quicker fix for pulse oximeters urged during FDA public meeting

Wegovy’s successful heart trial raises vital question about weight loss

Time to name cancers by genetics, not organ of origin, expert says

Wegovy’s successful heart trial raises vital question about weight loss

Biden administration opens offers in Medicare drug price negotiations

focus

focus

hotspot

entertainment